Trials / Recruiting
RecruitingNCT06419348
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- First Affiliated Hospital of Chongqing Medical University · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 99mTc-QULIC-5-P1 | Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1. |
Timeline
- Start date
- 2024-05-20
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2024-05-17
- Last updated
- 2025-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06419348. Inclusion in this directory is not an endorsement.